Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Science Translational Medicine|March 1, 2013
Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patientsAude G Chapuis, Gunnar B Ragnarsson, Hieu N Nguyen, et al.
JCI Insight|May 8, 2024
MR1-restricted T cell clonotypes are associated with "resistance" to Mycobacterium tuberculosis infectionDeborah L Cross, Erik D Layton, Krystle Kq Yu, et al.
Journal for Immunotherapy of Cancer|February 4, 2026
Dysregulated expression of the tumor suppressor p14ARF in cancer provides an effective target for TCR-T cell therapeuticsThomas M Schmitt, Kelsey Furiya, Cheryl Black, et al.
Nature Biomedical Engineering|October 22, 2025
Collagen-binding IL-12-armoured STEAP1 CAR-T cells reduce toxicity and treat prostate cancer in mouse modelsKoichi Sasaki, Vipul Bhatia, Yuta Asano, et al.
Medrxiv : the Preprint Server for Health Sciences|February 14, 2024
Expansion of the HSV-2-specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccineEmily S Ford, Alvason Li, Kerry J Laing, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 11, 2022
An In Vivo Model of Human Macrophages in Metastatic MelanomaValentin Voillet, Trisha R Berger, Kelly M McKenna, et al.
Plos One|June 6, 2024
qPCR assay for detection of Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Elements from CAR-T and TCR-T cells in fresh and formalin-fixed tissueShalini Pullarkat, Graeme Black, Marie Bleakley, et al.
JCI Insight|August 12, 2024
Expansion of the HSV-2-specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccineEmily S Ford, Alvason Z Li, Kerry J Laing, et al.
Transplantation and Cellular Therapy|May 17, 2026
Expert Panel Review and Practical Guidance on Biomarker Testing With Engineered Immune Effector CellsViktoria Blumenberg, Caroline Diorio, Jordan Gauthier, et al.
The Lancet. Oncology|July 6, 2023
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trialAndrew J Cowan, Margot J Pont, Blythe D Sather, et al.
Pageof 12